Conférence européenne sur la réduction des risques à Bâle

Ce nouveau film de l’HCLU, tourné lors de la seconde Conférence européenne sur la réduction des risques à Bâle, en Suisse, offre un aperçu des problèmes clés liés à la réduction des risques en Europe.

Pour en savoir plus, veuillez lire les informations ci-dessous (en anglais).

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

Drugreporter’s new movie, filmed at the the 2nd European Harm Reduction Conference in Basel, Switzerland, gives you an insight into the key issues surrounding harm reduction in Europe.

The turn of the century marked the start of a new, progressive era, in which harm reduction gained legitimacy, and programs were being expanded all over the region. Unfortunately, the global financial crisis had devastating consequences for harm reduction programs in Europe. Pragmatic, non-judgmental social and health services often fell victim to financial austerity measures or rising political populism. The booming market in new psychoactive drugs, the Hepatitis C epidemic, and the rising median age of the injecting drug user population, all pose many new challenges for service providers. In the Eastern part of Europe, where most programs have been funded by international donors, the Global Fund's decision to reduce its financial support has endangered the sustainability of newly-established harm reduction services. National governments do not seem to care, or (worse) have embraced the new wave of abstinence-only, zero-tolerance ideology. In some countries, such as Hungary and Bulgaria, this ideology fuels the criminalisation of drug users and leads, in turn, to more restrictive drug laws. The rise of Russian imperalism poses a clear and present danger for harm reduction in all countries bordering the EU. A good example is the Crimea, where the Russian occupiers have shut down opiate substitution programs, causing more than 800 clients to lose their right to survival.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.